Peculiarities of the choice of therapy for inflammatory bowel diseases associated with malignant neoplasms

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Article discusses the risks of various malignant neoplasms arising, with the exception of colorectal cancer, in patients with inflammatory bowel diseases and the impact of available treatment methods at such kind of risks. Peculiarities of choosing a therapy for inflammatory bowel diseases in patients with pre-existing malignant neoplasms are also discussed.

Full Text

Restricted Access

About the authors

Olga Y. Barysheva

V.A. Baranov Republican Hospital; Petrozavodsk State University

Author for correspondence.
Email: hosptherapy@mail.ru
ORCID iD: 0000-0002-2133-4849
SPIN-code: 4896-5434

MD, Dr. Sci. (Medicine), associate professor, professor of the Department of hospital therapy, A.P. Zilber Medical Institute, head of the Department of nephrology

Russian Federation, Petrozavodsk; Petrozavodsk

Anna M. Golubeva

V.A. Baranov Republican Hospital

Email: harloev@mail.ru
ORCID iD: 0009-0006-8073-9703

MD, gastroenterologist at Department of nephrology

Russian Federation, Petrozavodsk

Ksenia E. Egorova

V.A. Baranov Republican Hospital

Email: egorovake@mail.ru
ORCID iD: 0000-0003-4233-3906

MD, gastroenterologist at Department of nephrology

Russian Federation, Petrozavodsk

Natalia N. Vezikova

V.A. Baranov Republican Hospital; Petrozavodsk State University

Email: vezikov23@mail.ru
ORCID iD: 0000-0002-8901-3363
SPIN-code: 3910-7360

MD, Dr. Sci. (Medicine), professor, head of the Department of hospital therapy, A.P. Zilber Medical Institute 

Russian Federation, Petrozavodsk; Petrozavodsk

Darina D. Varlamova

Petrozavodsk State University

Email: darinavrlm@gmail.com
ORCID iD: 0000-0002-4015-5109
SPIN-code: 3901-0250

student of A.P. Zilber Medical Institute

Russian Federation, Petrozavodsk

References

  1. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023;17(6):827–54. PMID: 36528797. https://doi.org/10.1093/ecco-jcc/jjac187
  2. Клинические рекомендации. Язвенный колит. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская гастроэнтерологическая ассоциация. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 193_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/193_2 (дата обращения – 16.06.2025). [Clinical guidelines. Ulcerative colitis. Association of Coloproctologists of Russia, Russian Gastroenterological Association. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 193_2. URL: https://cr.minzdrav.gov.ru/preview-cr/193_2 (date of access – 16.06.2025) (In Russ.)].
  3. Клинические рекомендации. Болезнь Крона. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская гастроэнтерологическая ассоциация. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 176_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/176_2 (дата обращения – 16.06.2025). [Clinical guidelines. Crohn’s disease. Association of Coloproctologists of Russia, Russian Gastroenterological Association. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 176_2. URL: https://cr.minzdrav.gov.ru/preview-cr/176_2 (date of access – 16.06.2025) (In Russ.)].
  4. Sands BE, Irving PM, Hoops T, Izanec JL, Gao L-L, Gasink C et al.; SEAVUE Study Group. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–11. PMID: 35691323. https://doi.org/10.1016/S0140-6736(22)00688-2
  5. Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C et al. Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis through 5 years in Crohn’s disease and 4 years in ulcerative colitis. J Crohns Colitis. 2024;18(7):1091–1101. PMID: 38310565. PMCID: PMC11302965. https://doi.org/10.1093/ecco-jcc/jjae013
  6. Danese S, Hanauer SB, Jairath V, Mihaly E, Vicente Lidón R, Ott E et al. P457. Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s disease and ulcerative colitis. 17th Congress of ECCO; February 16–19, 2022. URL: https://www.ecco-ibd.eu/publications/congress-abstracts/item/p457-long-term-cumulative-safety-of-ustekinumab-in-bionaive-patients-with-crohn-s-disease-and-ulcerative-colitis.html (date of access – 16.06.2025).
  7. Long MD, Danese S, Ott E, Gasink C, Miao Y, Baker T et al. 14: Malignancies in patients treated with ustekinumab: Long-term pooled safety analysis in Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis through up to 5 years. Gastroenterology. 2022;162(7):S-5. https://doi.org/10.1016/S0016-5085(22)60014-3
  8. Hasan B, Tandon KS, Miret R, Khan S, Riaz A, Gonzalez A et al. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. J Gastroenterol Hepatol. 2022;37(6):1016–21. PMID: 35191100. https://doi.org/10.1111/jgh.15806
  9. Pang AS, Hudesman D, Chang S, Axelrad JE. Su1849: Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to ustekinumab. Gastroenterology. 2019;156(6):S-634–S-635. https://doi.org/10.1016/S0016-5085(19)38486-0
  10. Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: An updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024;22(3):499–512.e6. PMID: 37579866. PMCID: PMC10859547. https://doi.org/10.1016/j.cgh.2023.07.027
  11. Pans J, Loftus EV, Lacerda AP, Peyrin- Biroulet L, Dhaens G, Panaccione R et al. 114: Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: Results from a randomized phase 3 U-ENDURE maintenance study. Gastroenterología y Hepatología. 2023;46:90347. http://dx.doi.org/10.1016/S0210-5705(23)00246-7
  12. Massano A, Bertin L, Zingone F, Buda A, Visaggi P, Bertani L et al. Extraintestinal cancers in inflammatory bowel disease: A literature review. Cancers. 2023;15(15):3824. PMID: 37568640. PMCID: PMC10417189. https://doi.org/10.3390/cancers15153824
  13. Axelrad JE, Hashash JG, Itzkowitz SH. AGA clinical practice update on management of inflammatory bowel disease in patients with malignancy: Commentary. Clin Gastroenterol Hepatol. 2024;22(7):1365–72. PMID: 38752967. https://doi.org/10.1016/j.cgh.2024.03.032
  14. Mala A, Foteinogiannopoulou K, Koutroubakis IE. Solid extraintestinal malignancies in patients with inflammatory bowel disease. World J Gastrointest Oncol. 2021;13(12):1956–80. PMID: 35070035. PMCID: PMC8713323. https://doi.org/10.4251/wjgo.v13.i12.1956

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. 1. The frequency of new cases or recurrence of malignant neoplasms, depending on the treatment option for inflammatory bowel diseases*

Download (189KB)
Indexing metadata
3. 2. The risk of developing extra-intestinal malignancies in inflammatory bowel diseases, depending on the treatment option*

Download (722KB)
Indexing metadata

Copyright (c) 2025 Bionika Media